"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.
The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.
Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.
In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.
Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.
The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.
Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.
Denne historien er fra March 22, 2024-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra March 22, 2024-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Slimmer Side Effects
Weight-loss drugs have become hugely popular but can cause gastrointestinal issues. A breakthrough could be about to change that and also make treatment more affordable
AMERICA'S BEST NEW PRODUCTS 2025
VERY YEAR, COMPANIES PUSH THE BOUNDARIES OF CREATIVity and develop new products that promise to make your life healthier, more convenient and more fun.
HIGH WIRE ACT
FAULTY POWER LINES AND ELECTRICAL EQUIPMENT ARE BEING BLAMED FOR CAUSING DEADLY FIRES IN LOS ANGELES AND ACROSS THE U.S. IS ENOUGH BEING DONE TO PREVENT THESE DEVASTATING BLAZES?
Chelsea Handler
AS A SIX-TIME NEW YORK TIMES BESTSELLING AUTHOR, CHELSEA HANDLER knows the secret to a successful book is to stay true to herself.
Stephen Amell
WHILE IT SEEMED LIKE EVERYONE ON SOCIAL media was binge-watching Suits during the pandemic, there was one person who was intentionally not watching the long-running series that ended in 2019: Stephen Amell.
Not Seeing...But Believing
How COVID reshaped our understanding of invisible air particles and the spread of disease
The Strongman of Ecuador
Daniel Noboa's bravado, aggressive policies and alignment with Trumpian politics has positioned him as a formidable figure in Latin America. But his fight to retain the presidency isn't over
Spheres of Influence
Donald Trump is channeling the great power politics of past centuries to deal with China and Russia, experts tell Newsweek
AMERICA'S BEST LOYALTY PROGRAMS 2025
LOYALTY PROGRAMS HAVE BECOME A CORNERSTONE of the modern shopping experience, offering perks and rewards designed to keep customers returning for more.
Winning the Global Game
The U.S. holds more cards than China. Whether we keep our strategic advantage depends on how we play our hand
